Combination Chemotherapy, Peripheral Stem Cell Transplantation, and Biological Therapy in Treating Patients With Solid Tumors or Lymphoma

DISEASE CHARACTERISTICS:

• Diagnosis of solid tumor, Hodgkin's lymphoma, or B-cell non-Hodgkin's lymphoma
• Eligible for autologous stem cell transplantation
• No pleural effusion, pericardial effusion, or ascites
• No T-cell lymphoma

PATIENT CHARACTERISTICS:

Age:

• Under 57

Performance status:

• Karnofsky 80-100%

Life expectancy:

• Not specified

Hematopoietic:

• Not specified

Hepatic:

• Bilirubin no greater than 1.5 mg/dL (unless due to Gilbert's disease)
• SGOT or SGPT no greater than 2 times upper limit of normal
• Hepatitis B and C negative

Renal:

• Creatinine no greater than 2.0 mg/dL OR
• Creatinine clearance at least 60 mL/min

Cardiovascular:

• LVEF at least 50%
• No congestive heart disease
• No history of myocardial infarction within the past year
• No coronary artery disease
• No history of arrhythmia

Pulmonary:

• Diffusion capacity (corrected) at least 60%
• FEV_1 at least 65% of predicted

Other:

• HIV negative
• No history of seizures
• No mental disorders requiring medication (e.g., haloperidol)
• No active connective tissue disease
• No other malignancy within the past 5 years except basal cell or squamous cell skin cancer or any carcinoma in situ
• No allergy to gentamicin
• No hypersensitivity to E. coli-derived preparations
• No history of severe allergy to sargramostim (GM-CSF) or filgrastim (G-CSF)
• No systemic infection
• Not pregnant

PRIOR CONCURRENT THERAPY:

Biologic therapy:

• See Disease Characteristics

Chemotherapy:

• Not specified

Endocrine therapy:

• No concurrent corticosteroid therapy

Radiotherapy:

• Not specified

Surgery:

• Not specified

Other:

• No contrast dye for 3 weeks after completion of interleukin-2 therapy